Advertisement

Reactions Weekly

, Volume 1733, Issue 1, pp 207–207 | Cite as

Ipilimumab/nivolumab

Autoimmune hepatitis: case report
Case report
  • 18 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A 34-year-old woman developed autoimmune hepatitis while receiving treatment with ipilimumab and nivolumab for stage IV metastatic melanoma during pregnancy.

The woman, who was 7 weeks pregnant, presented for evaluation of a mass in the left breast in May 2016. She was diagnosed with mutated BRAF codon V600E stage IV metastatic melanoma with hepatic, pulmonary, bone, ipsilateral axillary and retro-pectoral lymph nodes involvement, and elevated LDH. She started receiving treatment with ipilimumab and nivolumab at FDA-approved doses during week 9 of pregnancy [routes and dosages not stated]. Two weeks into the ipilimumab and nivolumab treatment, she experienced pain in the left rib cage, which was due to a non-displaced pathologic bone fracture. She was then treated with...

Reference

  1. Burotto M, et al. Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. Seminars in Oncology 45: 164-169, No. 3, Jun 2018. Available from: URL: http://doi.org/10.1053/j.seminoncol.2018.03.003 - Chile

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations